Coronavirus (COVID-19) Current Therapy Global Market Report 2022 – By Drug Class (Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta), By Route Of Administration (Oral, Intravenous), By End User (Hospitals, Clinics, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : February 2022 | SKU CODE : 7646 | Delivery Time: 2-3 business days | Format :


The coronavirus (COVID-19) current therapy market consists of sales of drugs currently used for the treatment of COVID-19 infection. The market report includes single-drug therapeutics and combination drug therapeutics used in treating COVID-19 patients. The market consists of revenue generated by the companies that manufacture coronavirus current therapeutics by the sales of these products.

The main types of drugs in coronavirus (COVID-19) current therapy are remdesivir, hydroxychloroquine, ritonavir, lopinavir, interferon beta and others. Remdesivir is an antiviral drug that works by preventing an RNA-based virus from replicating its viral genome within an infected cell. It was first used to combat the Ebola virus. It can be administered through various routes such as oral and intravenous. The different sectors include hospitals, clinics, research institutes; others.

The global coronavirus (COVID-19) current therapy market is expected to decline from $28.16 billion in 2021 to $16.43 billion in 2022 at a compound annual growth rate (CAGR) of -41.7%. The decline in the COVID-19 current therapy market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The COVID-19 current therapy market is expected to decline to $1.57 billion in 2026 at a CAGR of -44.4%.

The outbreak of the pandemic COVID-19 contributed to the growth of coronavirus current therapy market. On March 11, 2020, the World Health Organization (WHO) declared the outbreak as a global pandemic. According to the World Health Organization (WHO), there were 10,719,946 cases of COVID-19 including 517,337 deaths reported to WHO as on 3rd July 2020, and this number is expected to grow soon. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs and the drug manufacturers are ramping up production to meet the global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to the patients as quickly as possible.

High costs involved in research and development of therapeutic drugs and vaccines and long waiting time required for each phase of clinical trials are expected to limit the growth of coronavirus (COVID-19) current therapy market. According to a recent study published in the Journal of Health Economics by Tufts Center for the Study of Drug Development, it is estimated to cost $2.6 billion in developing a new prescription medicine and gain marketing approval, and seven out of eight pipeline drugs will fail in the development process. Moreover, the time required for each phase of the clinical trial and drug approval process takes an average of 12 years for an experimental drug to reach the market. High costs and long waiting times for drug development are expected to hamper the coronavirus (COVID-19) current therapy market.

Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent Plasma therapy is a type of passive antibody therapy in which blood plasma is isolated from patients who have recovered from the disease of interest and administered to the patient with severe disease to suppress the virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection. According to guidance issued by the FDA, Convalescent Plasma Therapy is recommended as an investigational product during the public health emergency. By 30th April, 2020, around 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, around 7,774 patients have enrolled, and 3,809 of them have undergone convalescent plasma transfusion. The experimental convalescent plasma therapy is likely to gain attention if enough data is supporting the results.

In March 2020, Sanofi and Regeneron Pharmaceuticals planned to initiate clinical trials of rheumatoid arthritis drug Kevzara (sarilumab) for the treatment of COVID-19 symptoms. The US Food and Drug Administration (FDA) approved Kevzara to treat rheumatoid arthritis. The drug is part of an ongoing antibody partnership between Sanofi and Regeneron. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg.

Major players in the coronavirus (COVID-19) current therapy market are Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals.

North America is the largest region in the coronavirus (COVID-19) current therapy market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coronavirus (COVID-19) current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global coronavirus (COVID-19) current therapy market is segmented -

1) By Drug Type: Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, Others

2) By Route of Administration: Oral, Intravenous

3) By End-User: Hospitals, Clinics, Research Institutes, Others

    Table Of Contents

    1. Executive Summary

    2. Coronavirus (COVID-19) Current Therapy Market Characteristics

    3. Coronavirus (COVID-19) Current Therapy Market Trends And Strategies

    4. Impact Of COVID-19 On Coronavirus (COVID-19) Current Therapy

    5. Coronavirus (COVID-19) Current Therapy Market Size And Growth

    5.1. Global Coronavirus (COVID-19) Current Therapy Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Coronavirus (COVID-19) Current Therapy Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Coronavirus (COVID-19) Current Therapy Market Segmentation

    6.1. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Remdesivir

    Hydroxychloroquine

    Ritonavir

    Lopinavir

    Interferon Beta

    Others

    6.2. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Oral

    Intravenous

    6.3. Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospitals

    Clinics

    Research Institutes

    Others

    7. Coronavirus (COVID-19) Current Therapy Market Regional And Country Analysis

    7.1. Global Coronavirus (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Coronavirus (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market

    8.1. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Coronavirus (COVID-19) Current Therapy Market

    9.1. China Coronavirus (COVID-19) Current Therapy Market Overview

    9.2. China Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Coronavirus (COVID-19) Current Therapy Market

    10.1. India Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Coronavirus (COVID-19) Current Therapy Market

    11.1. Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Coronavirus (COVID-19) Current Therapy Market

    12.1. Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Coronavirus (COVID-19) Current Therapy Market

    13.1. Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Coronavirus (COVID-19) Current Therapy Market

    14.1. South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Coronavirus (COVID-19) Current Therapy Market

    15.1. Western Europe Coronavirus (COVID-19) Current Therapy Market Overview

    15.2. Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Coronavirus (COVID-19) Current Therapy Market

    16.1. UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Coronavirus (COVID-19) Current Therapy Market

    17.1. Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Coronavirus (COVID-19) Current Therapy Market

    18.4. France Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Coronavirus (COVID-19) Current Therapy Market

    19.1. Eastern Europe Coronavirus (COVID-19) Current Therapy Market Overview

    19.2. Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Coronavirus (COVID-19) Current Therapy Market

    20.1. Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Coronavirus (COVID-19) Current Therapy Market

    21.1. North America Coronavirus (COVID-19) Current Therapy Market Overview

    21.2. North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Coronavirus (COVID-19) Current Therapy Market

    22.1. USA Coronavirus (COVID-19) Current Therapy Market Overview

    22.2. USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Coronavirus (COVID-19) Current Therapy Market

    23.1. South America Coronavirus (COVID-19) Current Therapy Market Overview

    23.2. South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Coronavirus (COVID-19) Current Therapy Market

    24.1. Brazil Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Coronavirus (COVID-19) Current Therapy Market

    25.1. Middle East Coronavirus (COVID-19) Current Therapy Market Overview

    25.2. Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Coronavirus (COVID-19) Current Therapy Market

    26.1. Africa Coronavirus (COVID-19) Current Therapy Market Overview

    26.2. Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Coronavirus (COVID-19) Current Therapy Market Competitive Landscape And Company Profiles

    27.1. Coronavirus (COVID-19) Current Therapy Market Competitive Landscape

    27.2. Coronavirus (COVID-19) Current Therapy Market Company Profiles

    27.2.1. Moderna Therapeutics

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Novavax

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Bravovax

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Ascletis Pharma

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Altimmune

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Key Mergers And Acquisitions In The Coronavirus (COVID-19) Current Therapy Market

    29. Coronavirus (COVID-19) Current Therapy Market Future Outlook and Potential Analysis

    30. Appendix

    30.1. Abbreviations

    30.2. Currencies

    30.3. Research Inquiries

    30.4. The Business Research Company

    30.5. Copyright And Disclaimer

List Of Tables

    Table 1 Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2 Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5 Global Coronavirus (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6 Global Coronavirus (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7 Asia-Pacific, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8 Asia-Pacific, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9 China, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10 China, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11 India, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12 India, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13 Japan, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14 Japan, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15 Australia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16 Australia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17 Indonesia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18 Indonesia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19 South Korea, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20 South Korea, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21 Western Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22 Western Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23 UK, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24 UK, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25 Germany, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26 Germany, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27 France, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28 France, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29 Eastern Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30 Eastern Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31 Russia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32 Russia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33 North America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34 North America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35 USA, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36 USA, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37 South America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38 South America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39 Brazil, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40 Brazil, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41 Middle East, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42 Middle East, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43 Africa, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44 Africa, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45 Moderna Therapeutics Financial Performance
  • Table 46 Novavax Financial Performance
  • Table 47 Bravovax Financial Performance
  • Table 48 Ascletis Pharma Financial Performance
  • Table 49 Altimmune Financial Performance

List Of Figures

    Figure 1 Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2 Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 3 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4 Global Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5 Global Coronavirus (COVID-19) Current Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6 Global Coronavirus (COVID-19) Current Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7 Asia-Pacific, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8 Asia-Pacific, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9 China, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10 China, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11 India, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12 India, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13 Japan, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14 Japan, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15 Australia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16 Australia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17 Indonesia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18 Indonesia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19 South Korea, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20 South Korea, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21 Western Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22 Western Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23 UK, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24 UK, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25 Germany, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26 Germany, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27 France, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28 France, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29 Eastern Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30 Eastern Europe, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31 Russia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32 Russia, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33 North America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34 North America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35 USA, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36 USA, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37 South America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38 South America, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39 Brazil, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40 Brazil, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41 Middle East, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42 Middle East, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43 Africa, Coronavirus (COVID-19) Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44 Africa, Coronavirus (COVID-19) Current Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45 Moderna Therapeutics Financial Performance
  • Figure 46 Novavax Financial Performance
  • Figure 47 Bravovax Financial Performance
  • Figure 48 Ascletis Pharma Financial Performance
  • Figure 49 Altimmune Financial Performance
Global Contract Research And Manufacturing Services (CRAMS) Market Size, Forecasts, And Opportunities – Includes CRAMS Market Overview
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Remdesivir Global Market Report 2022 – By Route Of Administration (Oral, Intravenous), By Dosage Form (Tablets, Frozen Solution, Lypholized Solution), By Distribution Channel (Hospitals, Clinics, Drug Stores/Pharmacies, Online) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Hydroxychloroquine Global Market Report 2022 – By Drug Activity (Anti-Malarial Drug, Anti-Rheumatic Drug, Lupus Suppressant Drug, Anti COVID-19 Drug), By Formulation (Tablets, Injection), By Application (Malaria, Rheumatoid Arthritis, Lupus Erythematosus, COVID-19), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Speciality Drug Stores, Retail Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Interferons Global Market Report 2022 – By Type (Inteferon Alpha, Inteferon Beta, Inteferon Gamma), By Application (Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biosimilars Global Market Report 2022 – By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Drugs For Immunotherapy Global Market Report 2022 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors), By Therapy Area (Cancer, Autoimmune And Inflammatory Diseases, Infectious Diseases), By End User (Hospitals And Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Multiple Sclerosis Drugs Global Market Report 2022 – By Drug Class (Immunomodulators, Immunosuppressants, Interferons), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), By Route Of Administration (Oral Drugs, Parenteral Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Therapeutic Proteins Global Market Report 2022 – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders), By Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report